Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992599 | 0.92 | EGLN1 (0.54) | EGLN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16626254 | 0.88 | CYP1A2 (0.54) | EGLN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16626179 | 0.88 | EGLN1 (0.66) | EGLN1MAPK1MAPTHTTNPSR1 | |
| SCHEMBL14992929 | 0.84 | EGLN1 (0.42) | EGLN1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL14992102 | 0.84 | EGLN1 (0.40) | EGLN1MAPK1LMNAMAPTHTT | |
| SCHEMBL623047 | 0.81 | EGLN1 (0.80) | EGLN1 | |
| SCHEMBL16626185 | 0.81 | EGLN1 (0.63) | EGLN1 | |
| SCHEMBL21802965 | 0.80 | EGLN1 (0.66) | EGLN1 | |
| SCHEMBL627068 | 0.79 | EGLN1 (0.67) | EGLN1MAPK1MAPTHTTNPSR1 | |
| SCHEMBL16626196 | 0.79 | EGLN1 (0.66) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2021-04-13 | — | — | US | disclosed |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-26 | — | — | US | disclosed |
| US-9006251-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARAMCEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-20150045427-A1 | Oxaspiro[2.5]Octane Derivatives and Analogs | ZAFGEN, INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885CYP1A2 98/4885CYP3A4 352/4885 |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885CYP1A2 98/4885CYP3A4 352/4885 |
| US-20150045427-A1 | Oxaspiro[2.5]Octane Derivatives and Analogs | OXER1, ACOX3, OXGR1 | EGLN1 555/4885CYP1A2 180/4885CYP3A4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.